<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Vet Sci</journal-id><journal-id journal-id-type="iso-abbrev">Vet Sci</journal-id><journal-id journal-id-type="publisher-id">vetsci</journal-id><journal-title-group><journal-title>Veterinary Sciences</journal-title></journal-title-group><issn pub-type="epub">2306-7381</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40005940</article-id><article-id pub-id-type="pmc">PMC11861734</article-id><article-id pub-id-type="doi">10.3390/vetsci12020180</article-id><article-id pub-id-type="publisher-id">vetsci-12-00180</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Isolation, Genomic Characterization, and Immunogenicity Evaluation of a G9P[23] Porcine Rotavirus Strain</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Zixuan</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><xref rid="af1-vetsci-12-00180" ref-type="aff">1</xref><xref rid="af2-vetsci-12-00180" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Huang</surname><given-names>Wen</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><xref rid="af1-vetsci-12-00180" ref-type="aff">1</xref><xref rid="af2-vetsci-12-00180" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Yan</surname><given-names>Gengxuan</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af1-vetsci-12-00180" ref-type="aff">1</xref><xref rid="af2-vetsci-12-00180" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Tian</surname><given-names>Yuan</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><xref rid="af1-vetsci-12-00180" ref-type="aff">1</xref><xref rid="af2-vetsci-12-00180" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Chune</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><xref rid="af1-vetsci-12-00180" ref-type="aff">1</xref><xref rid="af2-vetsci-12-00180" ref-type="aff">2</xref><xref rid="af3-vetsci-12-00180" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Mao</surname><given-names>Xue</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><xref rid="af1-vetsci-12-00180" ref-type="aff">1</xref><xref rid="af2-vetsci-12-00180" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Sun</surname><given-names>Meng</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><xref rid="af1-vetsci-12-00180" ref-type="aff">1</xref><xref rid="af2-vetsci-12-00180" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Zhou</surname><given-names>Lu</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><xref rid="af1-vetsci-12-00180" ref-type="aff">1</xref><xref rid="af2-vetsci-12-00180" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Yu</surname><given-names>Chong</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af1-vetsci-12-00180" ref-type="aff">1</xref><xref rid="af2-vetsci-12-00180" ref-type="aff">2</xref><xref rid="c1-vetsci-12-00180" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Xia</surname><given-names>Haihua</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af1-vetsci-12-00180" ref-type="aff">1</xref><xref rid="af2-vetsci-12-00180" ref-type="aff">2</xref><xref rid="c1-vetsci-12-00180" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Carrasco</surname><given-names>Librado</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-vetsci-12-00180"><label>1</label>Institute of Microbiology, Heilongjiang Academy of Sciences, Harbin 150010, China</aff><aff id="af2-vetsci-12-00180"><label>2</label>National Key Laboratory of Agricultural Microbiology, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan 430070, China</aff><aff id="af3-vetsci-12-00180"><label>3</label>National Institutes for Food and Drug Control, Beijing 100050, China</aff><author-notes><corresp id="c1-vetsci-12-00180"><label>*</label>Correspondence: <email>yuchong137@163.com</email> (C.Y.); <email>haihuaxia@sina.com</email> (H.X.)</corresp></author-notes><pub-date pub-type="epub"><day>18</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>12</volume><issue>2</issue><elocation-id>180</elocation-id><history><date date-type="received"><day>02</day><month>1</month><year>2025</year></date><date date-type="rev-recd"><day>05</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>10</day><month>2</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract abstract-type="plain-language-summary"><title>Simple Summary</title><p>Species A rotaviruses are major pathogens that cause diarrhea in young children and animals. Porcine rotavirus A (PoRVA) G9-type is an emerging genotype with the potential for cross-species transmission between humans and swine, which causes economic losses to the livestock industry and threatens human and animal health. This study isolates and characterizes a novel porcine rotavirus strain, RHeN2 (G9P[23]), and evaluates its immunogenicity using two inactivation methods. It demonstrates the potential of RHeN2 as a candidate for a G9-type porcine rotavirus vaccine and identifies binary ethyleneimine as a superior inactivator compared with formaldehyde for preserving immunogenicity. The findings provide insights for the selection of inactivating agents for PoRVA vaccines and the development of G9-type vaccines.</p></abstract><abstract><title>Abstract</title><p>(1) Background: Rotavirus (RV) is the primary pathogen causing diarrhea in infants and young children. The G9-type is an emerging genotype; however, its isolation is challenging, and its immunogenicity to piglets is poorly understood. This study aimed to isolate, characterize, and evaluate the immunogenicity of a PoRVA strain, RHeN2, obtained from the diarrhea samples of piglets from a pig farm in Henan Province, China. (2) Methods: Porcine rotavirus A (PoRVA) was isolated from diarrheal samples of piglets on a farm in Henan Province, China, through sequential passaging on MA-104 cells. Its immunogenicity and cross-neutralization potential were evaluated. Inactivated vaccines were prepared using two agents (formaldehyde and binary ethyleneimine, BEI) and administered intramuscularly to 28-day-old piglets. Dulbecco&#x02019;s Modified Eagle Medium (DMEM) served as the control. (3) Results: A PoRVA strain, G9P[23] type, was successfully isolated and named RHeN2. Full-genome Sanger sequencing revealed the genetic constellation of this strain as G9-P[23]-I5-R1-C1- M1-A8-N1-T1-E1-H1. In addition, the titers of neutralizing antibodies peaked at 45 days post-vaccination, and the immunogenicity of the BEI-inactivated group of vaccines was better than that of the formaldehyde-inactivated group. The RHeN2 (G9P[23]) strain demonstrated a strong cross-neutralization ability against the same G9P[23] and G4P[23] strains and a stronger cross-neutralizing ability against the P[23] strains than against the P[7] strains. (4) Conclusion: The newly isolated G9P[23] strain demonstrates favorable immunogenicity, holding potential as a G9-type vaccine candidate.</p></abstract><kwd-group><kwd>porcine rotavirus</kwd><kwd>isolation</kwd><kwd>genome analysis</kwd><kwd>inactivated vaccine</kwd><kwd>neutralizing antibodies</kwd><kwd>cross-neutralization</kwd></kwd-group><funding-group><award-group><funding-source>National Key Research and Development Program of China</funding-source><award-id>2024YFF1504000</award-id></award-group><award-group><funding-source>Operation and service of the medical strain resource sub-library of the National Strain Resource Bank</funding-source><award-id>NMRC-2024-2</award-id></award-group><funding-statement>This research was funded by the National Key Research and Development Program of China (2024YFF1504000), and Operation and service of the medical strain resource sub-library of the National Strain Resource Bank (NMRC-2024-2).</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-vetsci-12-00180"><title>1. Introduction</title><p>Rotavirus (RV), a double-stranded RNA virus from the Reoviridae family, has a genome comprising 11 RNA segments encoding six structural (VP1&#x02013;VP4, VP6, and VP7) and six nonstructural (NSP1&#x02013;NSP5/6) proteins [<xref rid="B1-vetsci-12-00180" ref-type="bibr">1</xref>]. RV is classified into 10 species (RVA&#x02013;RVJ) based on the VP6 antigenic profile, all of which infect animals [<xref rid="B2-vetsci-12-00180" ref-type="bibr">2</xref>]. Five species (A, B, C, E, and H) have been identified in pigs, with species A rotavirus (RVA) having the highest prevalence [<xref rid="B3-vetsci-12-00180" ref-type="bibr">3</xref>]. Porcine rotavirus A (PoRVA) infections are detected in herds across all ages and primarily cause severe diarrhea in weaning and suckling piglets [<xref rid="B4-vetsci-12-00180" ref-type="bibr">4</xref>]. PoRVA exhibits substantial clinical and pathological similarities to transmissible gastroenteritis virus, porcine epidemic diarrhea virus, and porcine delta coronavirus, complicating their differentiation [<xref rid="B5-vetsci-12-00180" ref-type="bibr">5</xref>,<xref rid="B6-vetsci-12-00180" ref-type="bibr">6</xref>]. Co-infections or secondary infections involving these viruses are prevalent, cause economic losses to the livestock industry, and threaten human and animal health [<xref rid="B7-vetsci-12-00180" ref-type="bibr">7</xref>].</p><p>PoRVA remains prevalent in China and lives in pigs without causing clinical signs of diarrhea [<xref rid="B8-vetsci-12-00180" ref-type="bibr">8</xref>]. Recent analyses of the predominant PoRVA genotypes in China revealed that the primary VP7 genotypes in Shandong Province were G3, G5, and G9 [<xref rid="B9-vetsci-12-00180" ref-type="bibr">9</xref>]. In Taiwan, the prevalent VP7 genotypes are G9, G3, G4, and G5, while P[13], P[19], and P[23] are the dominant VP4 types [<xref rid="B10-vetsci-12-00180" ref-type="bibr">10</xref>]. In East China, G9, G1, and G5 are the main VP7 genotypes, and P[7], P[13], and P[23] are the most common VP4 genotypes [<xref rid="B11-vetsci-12-00180" ref-type="bibr">11</xref>]. The G9 PoRVA genotype, now dominant in Chinese pig herds, raises concerns about potential cross-species transmission between humans and pigs [<xref rid="B12-vetsci-12-00180" ref-type="bibr">12</xref>,<xref rid="B13-vetsci-12-00180" ref-type="bibr">13</xref>,<xref rid="B14-vetsci-12-00180" ref-type="bibr">14</xref>,<xref rid="B15-vetsci-12-00180" ref-type="bibr">15</xref>]. However, a vaccine targeting the G9-type PoRVA is currently unavailable in China.</p><p>Vaccination remains the primary strategy for preventing RV infections [<xref rid="B16-vetsci-12-00180" ref-type="bibr">16</xref>]. Compared to oral live-attenuated vaccines, inactivated rotavirus vaccines (IRV) are safer as they eliminate contamination risks and prevent the virus from regaining virulence [<xref rid="B17-vetsci-12-00180" ref-type="bibr">17</xref>]. They also avoid severe adverse reactions like intussusception [<xref rid="B18-vetsci-12-00180" ref-type="bibr">18</xref>,<xref rid="B19-vetsci-12-00180" ref-type="bibr">19</xref>,<xref rid="B20-vetsci-12-00180" ref-type="bibr">20</xref>]. Previous studies have demonstrated that IRV immunization induces the production of neutralizing anti-RV antibodies in mice and rhesus monkeys [<xref rid="B21-vetsci-12-00180" ref-type="bibr">21</xref>,<xref rid="B22-vetsci-12-00180" ref-type="bibr">22</xref>]. Additionally, IRV formulation for parenteral administration has received significant attention [<xref rid="B23-vetsci-12-00180" ref-type="bibr">23</xref>]. A vaccine candidate based on the G1P[8] strain has been tested in several animal models involving mice, rats, rabbits, and pigs, where it successfully triggered neutralizing antibody responses against various RV genotypes [<xref rid="B24-vetsci-12-00180" ref-type="bibr">24</xref>]. IRV immunization induces neutralizing antibodies in mice and rhesus monkeys, while a G1P[8]-based candidate vaccine has shown broad-spectrum cross-protection in multiple animal models. Current research on inactivated PoRVA vaccines, especially for emerging G9 strains, still has major knowledge gaps [<xref rid="B25-vetsci-12-00180" ref-type="bibr">25</xref>]. Key challenges like optimal inactivant selection, immunization protocol establishment, and sustained protective effects remain unresolved.</p><p>This study isolated and characterized the G9P[23] PoRVA strain RHeN2 from diarrheic piglets in a Henan swine farm, systematically evaluating its immunogenicity. Candidate vaccines were prepared using formaldehyde and binary ethylenimine (BEI) as inactivants. Neutralizing antibody levels in immunized piglets were dynamically monitored, and cross-neutralization assays against 11 heterologous PoRVA strains were conducted using sera collected at 31 days post-immunization to assess cross-protective capacity. These findings provide critical data for optimizing PoRVA-inactivated vaccine production processes and establish a scientific foundation for developing G9 genotype-specific vaccines.</p></sec><sec id="sec2-vetsci-12-00180"><title>2. Materials and Methods</title><sec id="sec2dot1-vetsci-12-00180"><title>2.1. Cells, Antibodies, and Viruses</title><p>The MA-104 cells used for isolating and propagating PoRVA were grown in a Dulbecco&#x02019;s modified eagle medium (DMEM; Gibco, Grand Island, NY, USA), supplemented with 10% fetal calf serum (OPCEL, Hohhot, China). The anti-PoRVA VP6 protein monoclonal antibody (VP6-3B8) preserved in our laboratory, as well as a monoclonal antibody (R-4C2) utilizing different PoRVA genotypes provided by Dr. Wen Huang from Huazhong Agricultural University, were prepared as described here. First, BALB/c mice were immunized with PoRVA VP6 protein or inactivated PoRVA viral particles. Subsequently, their splenocytes were fused with Sp2/0 myeloma cells to generate hybridoma cells, which were screened and selected. The PoRVA strains RShanD1, ShanX3, RFuJ4, RHuN6, RHaiN7, and RHeN8 were isolated from clinical piglet diarrhea samples and stored in our laboratory. Strains KQ1 (G1P[7]), KQ2 (G3P[23]), KQ3 (G4P[23]), KQ4 (G5P[23]), and KQ5 (G9P[23]) were kindly provided by Wuhan Keqian Biology Co., Ltd. (Wuhan, China).</p></sec><sec id="sec2dot2-vetsci-12-00180"><title>2.2. Clinical Samples Preparation</title><p>The PoRVA strain was isolated from five intestinal tissue samples of piglets with diarrhea, which were obtained from large-scale pig farms in Henan Province, China, in late 2021. Viral RNA was extracted using the TRIzol reagent, and cDNA was subsequently synthesized with the TaKaRa RNA PCR Kit (AMV) (Ver.3.0, TaKaRa Biomedical Technology, Beijing, China), following the manufacturer&#x02019;s guidelines. The presence of viral nucleic acids was confirmed through RT-PCR, using the synthesized cDNA as templates and primers targeting the PoRVA VP7 gene (<xref rid="vetsci-12-00180-t001" ref-type="table">Table 1</xref>) [<xref rid="B26-vetsci-12-00180" ref-type="bibr">26</xref>]. For viral isolation, the inoculum was prepared by mixing 5 mL of DMEM with 1 mL of intestinal contents positive for PoRVA. The mixture was vortexed for 5 min, centrifuged at 4000&#x000d7; <italic toggle="yes">g</italic> and 4 &#x000b0;C for 10 min to remove cellular debris, and filtered through a 0.22-&#x003bc;m filter. The resulting filtered supernatant was used as the inoculum for PoRVA isolation.</p></sec><sec id="sec2dot3-vetsci-12-00180"><title>2.3. Virus Isolation</title><p>PoRVA isolation was performed using MA-104 cells. The filtered supernatant (500 &#x000b5;L) was combined with trypsin (10 &#x000b5;g/mL), vortexed to ensure thorough mixing, and incubated for 1 h at 37 &#x000b0;C in a 5% CO<sub>2</sub> atmosphere [<xref rid="B27-vetsci-12-00180" ref-type="bibr">27</xref>]. MA-104 cells cultured in six-well plates were washed with phosphate-buffered saline (PBS) and inoculated with the prepared supernatant. Each well was supplemented with 1.5 mL of a serum-free DMEM containing 3.33 &#x000b5;g/mL trypsin. After 1 h of virus adsorption, the cells were washed twice with PBS to remove unbound viral particles, followed by the addition of 2 mL of a serum-free DMEM containing 5 &#x000b5;g/mL trypsin. Cells were monitored daily for cytopathic effects (CPEs) until harvest.</p><p>After harvesting, the cell culture was subjected to three freeze-thaw cycles to facilitate viral release. Subsequently, the sample was centrifuged at 5000&#x000d7; <italic toggle="yes">g</italic> for 10 min, and the supernatant was collected. This supernatant was aliquoted into smaller volumes and stored at &#x02212;80 &#x000b0;C to serve as the F0 generation virus. Serial passaging was performed in T25 cell culture flasks for virus propagation. If CPEs were not observed within 4 days post-inoculation, the flasks underwent three additional freeze-thaw cycles, followed by centrifugation and supernatant collection, enabling continued passaging for three blind passages, after which a PCR assay was performed. If the assay yielded positive results, passaging was continued; negative results led to the discarding of the inoculated cells.</p></sec><sec id="sec2dot4-vetsci-12-00180"><title>2.4. Immunofluorescence Assay (IFA)</title><p>PoRVA isolates were inoculated into MA-104 cells in 24-well plates at a multiplicity of infection (MOI) of 0.1, with a negative control established after 24 h. The cells were fixed with 4% paraformaldehyde, permeabilized with methanol, and blocked with 5% Bovine serum albumin (BSA). After three washes with PBS, the cells were incubated with a monoclonal antibody (dilution: 1000&#x000d7;) and a FITC-conjugated secondary antibody. The nuclei were counterstained with DAPI, and fluorescence images were captured using a fluorescence microscope (Nikon, Tokyo, Japan).</p></sec><sec id="sec2dot5-vetsci-12-00180"><title>2.5. Transmission Electron Microscopic (TEM) Observation</title><p>The virus-containing supernatant was centrifuged at 3000&#x000d7; <italic toggle="yes">g</italic> and 4 &#x000b0;C for 10 min, followed by filtration through a 0.22-&#x000b5;m membrane to remove cell debris. The filtered supernatant was added to an ultrafiltration device (Millipore, Amicon Ultra, Boston, MA, USA) and centrifuged at 4000&#x000d7; <italic toggle="yes">g</italic> and 4 &#x000b0;C for 10 min (repeated as necessary) until the sample volume was reduced to the target volume. Subsequently, the ultrafiltration device was inverted and placed into a new collection tube, followed by centrifugation at 1000&#x000d7; <italic toggle="yes">g</italic> for 2 min to collect the concentrated virus sample. Next, the concentrated sample was subjected to initial purification using a Capto Core 700 chromatography column (Cytiva, Marlborough, MA, USA), followed by further purification using an AKTA protein purification system. After purification, the virus concentration was measured using a NanoDrop 2000 spectrophotometer (Thermo Scientific<sup>TM</sup>, Waltham, MA, USA). To observe the virus morphology, 10 &#x000b5;L of the purified virus suspension was carefully applied to a copper grid and incubated for 10 min. Furthermore, 10 &#x000b5;L of phosphotungstic acid solution was added for negative staining, followed by an additional 10-min incubation. Finally, the virus samples were observed using a Hitachi H-7650 transmission electron microscope (Tokyo, Japan).</p></sec><sec id="sec2dot6-vetsci-12-00180"><title>2.6. Viral Growth Curve Determination</title><p>The 10th passage of the PoRVA isolate was inoculated onto MA-104 cells in 24-well plates at an MOI of 0.2. Supernatants were harvested at various time points (8, 16, 24, 28, 32, 36, 40, 44, 52, and 60 h post-inoculation, hpi) to determine the median tissue culture infective dose (TCID<sub>50</sub>). The procedure was as follows: First, the cell monolayer was washed three times with PBS. Then, 100 &#x000b5;L of the supernatants was mixed with 900 &#x000b5;L of DMEM to prepare serial dilutions from 10<sup>&#x02212;1</sup> to 10<sup>&#x02212;9</sup>. Each dilution was inoculated onto the cell monolayer at 100 &#x000b5;L per well, with eight replicates per dilution, alongside negative controls containing only medium. The plate was incubated at 37 &#x000b0;C, and CPEs were observed and recorded daily under a microscope for 5 days to determine the viral titers. Each time point was independently measured in triplicate. Finally, TCID<sub>50</sub> was calculated using the Reed&#x02013;Muench method [<xref rid="B28-vetsci-12-00180" ref-type="bibr">28</xref>]. The growth curve of the isolate was plotted using GraphPad Prism 8.4.3 (GraphPad Software, La Jolla, CA, USA).</p></sec><sec id="sec2dot7-vetsci-12-00180"><title>2.7. Whole-Genome Sequencing Analysis</title><p>The total RNA was extracted from the cell culture samples using Omega Bio-tek<sup>&#x000ae;</sup> Total RNA Extraction Kit I (Omega Biotech, Norcross, GA, USA). Reverse transcription to cDNA was performed with Reverse Transcription Kit R212 (Vazyme, Nanjing, China). Based on the conserved regions of the entire PoRVA genome, 11 pairs of specific primers were designed (<xref rid="vetsci-12-00180-t002" ref-type="table">Table 2</xref>). High-fidelity amplification was performed using Phanta Max<sup>&#x000ae;</sup> Super-Fidelity DNA Polymerase P505 (Vazyme Biotech Co., Ltd., Nanjing, China). The amplified bands were purified using EasyPure<sup>&#x000ae;</sup> PCR Purification Kit (TransGen Biotech Co., Ltd., Beijing, China). The purified products were sent to Qingke Biotechnology Co., Ltd. (Beijing, China) for Sanger sequencing. After the raw data were assembled by SeqMan (DNASTAR Lasergene 17, Madison, WI, USA), multiple sequence alignment and phylogenetic analysis were conducted using MEGA11 [<xref rid="B29-vetsci-12-00180" ref-type="bibr">29</xref>].</p></sec><sec id="sec2dot8-vetsci-12-00180"><title>2.8. Neutralization Test</title><p>The virus neutralization assay was conducted in 96-well cell culture plates to determine the serum-neutralizing antibody titers. MA-104 cells were seeded at a density of 2 &#x000d7; 10<sup>4</sup> cells/well and cultured for 24 h. The RHeN2 strain culture was diluted to 200 TCID<sub>50</sub>/50 &#x000b5;L using serum-free DMEM. Equal volumes (50 &#x000b5;L) of the diluted virus and serially diluted serum samples (starting from 1:8 to 1:2048) were mixed in a 96-well plate and incubated at 37 &#x000b0;C for 1 h. The virus&#x02013;serum mixture was then added to the MA-104 cell monolayer and incubated at 37 &#x000b0;C for 1 h. After incubation, the cells were washed three times with PBS and maintained in DMEM supplemented with 2% fetal bovine serum at 37 &#x000b0;C in a 5% CO<sub>2</sub> incubator for 72 h. The neutralizing antibody titer (ND<sub>50</sub>) was determined using the Reed&#x02013;Muench method, defined as the highest serum dilution that inhibited 50% of the CPEs [<xref rid="B28-vetsci-12-00180" ref-type="bibr">28</xref>].</p></sec><sec id="sec2dot9-vetsci-12-00180"><title>2.9. Preparation of Inactivated Vaccines</title><p>For the BEI-inactivated vaccine, bromoethylamine hydrobromide was first mixed with a PBS solution containing 0.5 M sodium hydroxide and incubated for 1 h in a 37 &#x000b0;C water bath to generate a 0.2 M BEI inactivating agent, which was filtered and sterilized for later use. Subsequently, the BEI inactivating agent was added to the purified RHeN2 virus solution at a volume ratio of 1:40, followed by inactivation for 48 h at 37 &#x000b0;C. The reaction was terminated by adding sodium thiosulfate to a final concentration of 2% [<xref rid="B30-vetsci-12-00180" ref-type="bibr">30</xref>]. For the formaldehyde-inactivated vaccine, the purified virus solution was mixed with 0.2% formaldehyde and inactivated for 72 h at 37 &#x000b0;C. Next, 1% sodium bisulfite was slowly added, and the mixture was allowed to react for 30 min at 37 &#x000b0;C to completely neutralize the formaldehyde, forming non-toxic hydroxymethyl sulfonate. The neutralization effect was verified using a potassium iodide-starch test paper. The inactivated virus solution was inoculated onto MA-104 cells and observed for 4&#x02013;6 days. If no CPE was observed, the solution was blindly passaged for three additional generations to confirm the absence of infectivity, while sterility testing was conducted to ensure aseptic conditions. Finally, an equal proportion of adjuvant (Montanide&#x02122; ISA 201<sup>&#x000ae;</sup>, SEPPIC, Paris, France) was added to both inactivated vaccines for formulation. The entire preparation process strictly followed inactivation, neutralization, and safety verification steps to ensure complete virus inactivation, thorough removal of formaldehyde residues, and validation of the vaccine&#x02019;s safety and immunogenicity.</p></sec><sec id="sec2dot10-vetsci-12-00180"><title>2.10. Immunization of Piglets with Inactivated PoRVA RHeN2 Vaccine</title><p>Fifteen 28-day-old piglets with PoRVA-neutralizing antibody titers &#x02264;1:10 were randomly assigned to three groups (<xref rid="vetsci-12-00180-t003" ref-type="table">Table 3</xref>). A randomized controlled trial was conducted to assess the immunogenicity of the PoRVA-inactivated vaccine. The experimental group (<italic toggle="yes">n</italic> = 10) was intramuscularly injected with the inactivated vaccine containing 50% adjuvant (2 mL/dose), followed by a second immunization using the same method and dose after 2 weeks. The control group (<italic toggle="yes">n</italic> = 5) received an intramuscular injection of DMEM containing 50% adjuvant (2 mL/dose). Serum was collected at 15 weeks to assess the immune response. As described in <xref rid="sec2dot8-vetsci-12-00180" ref-type="sec">Section 2.8</xref>, serum neutralization titers were determined for each sample using RHeN2 strain.</p></sec><sec id="sec2dot11-vetsci-12-00180"><title>2.11. Statistical Analysis</title><p>Statistical analyses were performed using GraphPad Prism 8.4.3 (GraphPad Software, CA, USA). Multiple comparisons were conducted using Student&#x02019;s <italic toggle="yes">t</italic>-test and one-way/two-way analysis of variance. The data were presented as means &#x000b1; standard deviations, and <italic toggle="yes">p</italic> &#x0003c; 0.05 was considered statistically significant.</p></sec></sec><sec sec-type="results" id="sec3-vetsci-12-00180"><title>3. Results</title><sec id="sec3dot1-vetsci-12-00180"><title>3.1. Virus Isolation</title><p>The virus was isolated from five PoRVA samples that were RT-PCR positive. In the blind passages of the third generation of MA-104 cells, samples from Henan showed CPEs primarily characterized by cell rounding, aggregation, lysis, and detachment (<xref rid="vetsci-12-00180-f001" ref-type="fig">Figure 1</xref>A), consistent with the CPEs caused by PoRVA. It was named the PoRVA RHeN2 strain based on its origin. RT-PCR detection of the F3&#x02013;F5 generations of the viral solution from the strains produced specific amplification bands of 333 bp (<xref rid="vetsci-12-00180-f001" ref-type="fig">Figure 1</xref>B), indicating that the isolated virus was PoRVA and could proliferate stably in MA-104 cells.</p><p>The proliferation of the PoRVA virulent strain RHeN2 in MA-104 cells was confirmed through IFA using a monoclonal antibody targeting the PoRVA VP6 protein (<xref rid="vetsci-12-00180-f001" ref-type="fig">Figure 1</xref>A). Immunofluorescence specific for the PoRVA VP6 protein was observed in most cells 16 hpi, with the VP6 protein predominantly localized in the cytoplasm. In contrast, no fluorescence was detected in the control group.</p><p>TEM revealed particles of the purified RHeN2 virus strain infecting MA-104 cells. Negative staining under electron microscopy revealed typical wheel-shaped particles with a radial arrangement from the center to the periphery, measuring approximately 70 nm in diameter (<xref rid="vetsci-12-00180-f001" ref-type="fig">Figure 1</xref>C).</p></sec><sec id="sec3dot2-vetsci-12-00180"><title>3.2. Virus Growth Characterization</title><p>To elucidate the growth kinetics of the RHeN2 strain, MA-104 cells were infected with the 10th passage of RHeN2 at an MOI of 0.2, and viral titers were measured at various time points to generate a growth curve (<xref rid="vetsci-12-00180-f002" ref-type="fig">Figure 2</xref>). The results revealed a typical biphasic replication pattern: during the 8&#x02013;28 hpi period, the average viral titer increased significantly from 10<sup>4.63</sup> TCID<sub>50</sub>/mL to a peak of 10<sup>8.5</sup> TCID<sub>50</sub>/mL (<italic toggle="yes">p</italic> &#x0003c; 0.05), indicating rapid viral replication during the early infection phase. After 28 hpi, the virus entered a plateau phase, with no significant differences in viral titers between adjacent time points (<italic toggle="yes">p</italic> &#x0003e; 0.05), suggesting a dynamic equilibrium between viral replication and host cell antiviral responses. Notably, this replication pattern remained stable during subsequent passages, with the peak titer consistently observed at 28 hpi, confirming that the RHeN2 strain exhibits stable growth kinetics.</p></sec><sec id="sec3dot3-vetsci-12-00180"><title>3.3. Whole-Genome Sequence of the RHeN2 Strain</title><p>The isolate was confirmed as PoRVA through Sanger sequencing and subsequent BLAST analysis against GenBank entries (<xref rid="vetsci-12-00180-t004" ref-type="table">Table 4</xref>). The genomic sequence of this strain (G9-P[23]-I5-R1-C1-M1-A8-N1-T1-E1-H1) has been deposited in GenBank under accession numbers PV026137 to PV026147. Comparative analysis of coding sequences revealed distinct phylogenetic relationships: eight gene segments (VP1, VP2, VP4, VP6, VP7, NSP2, NSP4, and NSP5) exhibited the highest nucleotide identity to PoRVA reference strains (99.94%, 97.23%, 95.71%, 96.21%, 99.68%, 97.36%, 97.97%, and 97.74%, respectively). In contrast, three segments (VP3, NSP1, and NSP3) showed closer homology to human rotavirus A (HRVA) strains, with nucleotide identities of 96.84%, 95.57%, and 96.83%, respectively.</p></sec><sec id="sec3dot4-vetsci-12-00180"><title>3.4. Phylogenetic Analysis</title><p>The RHeN2 strain was classified as I5 via the analysis of the VP6 gene, demonstrating the highest nucleotide homology (96.21% nt) with the porcine RV CHN/GZ/GX3/2022/G5 (<xref rid="vetsci-12-00180-f003" ref-type="fig">Figure 3</xref>A). Regarding the VP7 gene, there are six recognized VP7 G9 lineages (Lineages I&#x02013;VI) [<xref rid="B31-vetsci-12-00180" ref-type="bibr">31</xref>]. RHeN2 was placed within Lineage VI of the six recognized VP7 G9 lineages (<xref rid="vetsci-12-00180-f003" ref-type="fig">Figure 3</xref>B), showing close alignment with the Chinese strain CHN/CY/LH9/2022/G9, with a nucleotide identity of 99.68%. For the VP4 gene, RHeN2 exhibited a nucleotide identity of 95.71% with the Chinese strain RVA/Pig/China/NMTL/2008/G9P[23] (<xref rid="vetsci-12-00180-f003" ref-type="fig">Figure 3</xref>C). Concerning VP1, RHeN2 shared the highest nucleotide identity (99.94% nt) with the porcine strain K71 (<xref rid="vetsci-12-00180-f003" ref-type="fig">Figure 3</xref>D). The VP2 gene of RHeN2 exhibited close clustering with the porcine strain RVA/Pig-wt/CHN/923E/2021/G9P[23], demonstrating a nucleotide identity of 97.23% (<xref rid="vetsci-12-00180-f003" ref-type="fig">Figure 3</xref>E). For the VP3 gene, RHeN2 was most similar to the human strain RVA/human-tc/VNM/NT0042/2007/G4P[6], with a nucleotide identity of 96.84% (<xref rid="vetsci-12-00180-f003" ref-type="fig">Figure 3</xref>F). Considering NSP1, RHeN2 displayed the highest homology (95.57% nt) with the human-origin strain Mc345 (<xref rid="vetsci-12-00180-f003" ref-type="fig">Figure 3</xref>G). The NSP2 gene of RHeN2 exhibited the highest similarity degree to the porcine strain JSJR2023, sharing a nucleotide identity of 97.36% (<xref rid="vetsci-12-00180-f003" ref-type="fig">Figure 3</xref>H). For NSP3, RHeN2 clustered closely with the human strain RVA LL3345, with a nucleotide identity of 96.83% (<xref rid="vetsci-12-00180-f003" ref-type="fig">Figure 3</xref>I). Analysis of NSP4 revealed that RHeN2 exhibited the highest homology (97.97% nt) with the porcine strain RVA/Pig-wt/CHN/GDFZ/2023/G9P[23] (<xref rid="vetsci-12-00180-f003" ref-type="fig">Figure 3</xref>J). Finally, for the NSP5 gene, RHeN2 showed the greatest similarity (97.74% nt) with the Chinese strain RVA/Pig-wt/CHN/CN127/2021/G12P[7] (<xref rid="vetsci-12-00180-f003" ref-type="fig">Figure 3</xref>K).</p></sec><sec id="sec3dot5-vetsci-12-00180"><title>3.5. Immunogenicity of the RHeN2 Strain in Piglets</title><p>To assess the immunogenicity of the RHeN2 strain and the effects of various inactivators on its immunological potential, animal trials were conducted according to the methodology outlined in the Materials and Methods section. Piglets (28 days old) were intramuscularly administered with 2 mL of RHeN2 that had been inactivated using 0.005 mol/L BEI, 0.2% formaldehyde, or DMEM as the control. A booster dose was administered 2 weeks after the initial injection. Serum samples were collected on designated days post-vaccination (dpv), and serum neutralization titers were measured (<xref rid="vetsci-12-00180-f004" ref-type="fig">Figure 4</xref>A). At 14 dpv, neutralizing antibodies, with titers no less than 1:40, were detected in the immunized piglets (<xref rid="vetsci-12-00180-f004" ref-type="fig">Figure 4</xref>B). Antibody levels continued to increase and peaked at 45 dpv. The mean neutralizing antibody titers in the BEI-inactivated vaccine group were significantly greater than those in the formaldehyde-inactivated vaccine group. The BEI-inactivated group had an average neutralizing titer of 1:843, while the formaldehyde-inactivated group showed a titer of 1:544.4. By 59 dpv, serum-neutralizing antibody levels began to decline gradually. At 73 dpv, a more significant decrease was observed, although antibody levels remained relatively high through 101 dpv. At this point, the mean neutralizing antibody titer in the BEI-inactivated vaccine group was 1:299.6, whereas the formaldehyde-inactivated vaccine group had a titer of 1:211.2. The results demonstrate that the inactivated vaccine prepared from the PoRVA RHeN2 strain exhibits favorable immunogenicity. As a vaccine inactivator, BEI shows superior efficacy compared to the traditional formaldehyde inactivation method. BEI more effectively preserves the immunogenic epitopes of the virus, thereby inducing a relatively stronger and more sustained immune response in the host.</p></sec><sec id="sec3dot6-vetsci-12-00180"><title>3.6. The Cross-Neutralizing Activity of the Inactivated RHeN2 Vaccine Against 11 Strains of PoRVA Strains</title><p>To evaluate the cross-protective efficacy of the PoRVA RHeN2 (G9P[23]) inactivated vaccine against other PoRVA strains, we conducted a cross-neutralization assay using sera collected from five piglets in the BEI-inactivated vaccine group (31 days post-vaccination) against 11 different PoRVA strains [RShanD1 (G5P[7]), RShanX3 (G9P[23]), RFuJ4 (G9P[7]), RHuN6 (G9P[23]), RHaiN7 (G4P[7]), RHeN8 (G4P[23]), KQ1 (G1P[7]), KQ2 (G3P[23]), KQ3 (G4P[23]), KQ4 (G5P[23]), and KQ5 (G9P[23])] (<xref rid="vetsci-12-00180-f005" ref-type="fig">Figure 5</xref>). Analysis of neutralizing antibody levels revealed that the immune sera exhibited the highest neutralizing activity against the homologous strain RHeN2 (G9P[23]), with an average titer of 357.4. The sera also showed high neutralizing activity against strains of the same genotype (G9P[23]), including RShanX3, RHuN6, and KQ5, with average titers of 264.4, 240.0, and 220.0, respectively, showing no significant difference compared to the homologous strain. Additionally, the immune sera demonstrated high neutralizing activity against G4P[23] genotype strains (RHeN8 and KQ3), with average titers of 220.2 and 231.6, respectively, and no significant difference compared to the homologous strain. However, the neutralizing activity against strains of other genotypes was significantly reduced (<italic toggle="yes">p</italic> &#x0003c; 0.0001), with average titers of 84.6, 71.6, 67.2, 60.0, 23.2, and 19.2 against G5P[23] (KQ4), G3P[23] (KQ2), G9P[7] (RFuJ4), G5P[7] (RShanD1), G1P[7] (KQ1), and G4P[7] (RHaiN7) strains, respectively. These results indicate that the RHeN2 (G9P[23]) inactivated vaccine provides significant cross-protection against G9P[23] and G4P[23] genotype strains but offers limited protection against strains of other genotypes. This finding provides important insights for the clinical application and optimization of immunization strategies for PoRVA G9-type vaccines.</p></sec></sec><sec sec-type="discussion" id="sec4-vetsci-12-00180"><title>4. Discussion</title><p>The isolation and propagation of G9-type in cell cultures are usually challenging, possibly owing to its high dependence on trypsin [<xref rid="B32-vetsci-12-00180" ref-type="bibr">32</xref>]. Trypsin plays a critical role in RV infection by cleaving the viral surface protein VP4 into VP5* and VP8* polypeptides, enhancing virus&#x02013;host cell interaction and infectivity [<xref rid="B33-vetsci-12-00180" ref-type="bibr">33</xref>]. Direct virus inoculation onto cells results in low isolation efficiency. To address this, we introduced a trypsin pre-treatment approach and optimized trypsin concentration, significantly improving PoRVA isolation and propagation in MA-104 cells. Experiments showed stable virus propagation at trypsin concentrations &#x02265;5 &#x000b5;g/mL. However, to mitigate potential cytotoxicity (e.g., altered cell morphology and reduced viability), we used 10 &#x000b5;g/mL trypsin during pre-treatment and reduced it to 5 &#x000b5;g/mL during cell inoculation. This optimized protocol provides reliable technical support for further research and represents a valuable reference for isolating other challenging RV strains.</p><p>The detection rate of PoRVA in pig farms has increased recently, and the prevalent genotypes have changed significantly, evolving from a predominantly G5-type to a predominantly G9-type [<xref rid="B34-vetsci-12-00180" ref-type="bibr">34</xref>,<xref rid="B35-vetsci-12-00180" ref-type="bibr">35</xref>]. In this study, PoRVA strains were isolated from the intestinal samples of piglets with diarrhea in Henan Province, China. We sequenced the VP4 and VP7 genes of these strains and identified them as the G9P[23] type. The emergence of new strains poses an economic threat to the livestock industry and a risk to human and animal health. Studies have demonstrated that G9 PoRVA offers complete short-term cross-protection against HRV and PoRVA, while HRV provides only partial protection against PoRVA [<xref rid="B36-vetsci-12-00180" ref-type="bibr">36</xref>]. Therefore, developing a vaccine specifically aimed at G9 PoRVA is vital for effectively managing its spread. Furthermore, genomic analyses reveal that G9 strains exhibit dual tropism, infecting both pigs and humans, with significant genetic diversity observed among circulating strains [<xref rid="B37-vetsci-12-00180" ref-type="bibr">37</xref>,<xref rid="B38-vetsci-12-00180" ref-type="bibr">38</xref>]. The presence of recombinant variants in pig populations and human cohorts highlights the potential for cross-species transmission, driven by genetic similarities between pig and human G9 strains. Notably, we observed that the VP3, NSP1, and NSP3 proteins of the RHeN2 strain are highly homologous with those of HRVA. Moreover, phylogenetic analyses of human G9 RVs have shown that they are more closely related to porcine G9 strains than to earlier human G9-types [<xref rid="B39-vetsci-12-00180" ref-type="bibr">39</xref>]. These findings underscore the potential public health risks posed by PoRVA.</p><p>Vaccination remains the primary strategy for preventing severe diarrhea caused by RV. Inactivated vaccines offer several advantages over live vaccines, including a reduced risk of contamination by exogenous factors and the absence of concerns related to virulence reversion. Notably, inactivated vaccines effectively mitigate the occurrence of severe adverse reactions, such as intussusception, and can be easily combined with other vaccines. These characteristics are crucial for the effective control of RV infections and the reduction of mortality rates associated with severe diarrhea in piglets. To evaluate the immunogenicity of the inactivated vaccine of the virulent strain, we used two inactivation methods to select the inactivating agent: 2% formaldehyde and 5 mM BEI. By comparing the inactivation effects of formaldehyde and BEI on PoRVA, we provided a valuable reference for research on the inactivation process for the development of a PoRVA-inactivated vaccine. Formaldehyde is the most common inactivation agent [<xref rid="B40-vetsci-12-00180" ref-type="bibr">40</xref>]. BEI interacts with nucleic acids, destroying their structure and completely inactivating the virus. Meanwhile, it does not damage the surface structural proteins of the virus, which retain their antigenicity, and BEI does not remain in the host [<xref rid="B41-vetsci-12-00180" ref-type="bibr">41</xref>]. Throughout the detection period, neutralizing antibody levels in the BEI-inactivated vaccine group were consistently higher than those in the formaldehyde-inactivated vaccine group. This suggests that BEI inactivation had a lesser effect on the immunogenicity of the PoRVA G9P[23] strain than formaldehyde inactivation. These findings offer valuable insights for selecting appropriate inactivating agents in the development of future inactivated vaccines targeting the G9P[23] strain. We tested the cross-neutralizing activity of the inactivated G9P[23] RV vaccine with prevalent strains of multiple other genotypes in piglets. The results showed that the inactivated RHeN2 vaccine had a strong cross-neutralizing ability against the same G9P[23] and G4P[23] strains and a stronger cross-neutralizing ability against the P[23] strains than against the P[7] strains. This suggests that the RHeN2 (G9P[23]) immune serum produces a good neutralizing response against the currently prevalent strains of multiple genotypes and represents a promising candidate vaccine strain.</p></sec><sec sec-type="conclusions" id="sec5-vetsci-12-00180"><title>5. Conclusions</title><p>The PoRVA strain RHeN2 (G9P[23]) was successfully isolated and subcultured in MA-104 cells. Its biological characteristics were characterized through IFA and TEM, with the viral titer peaking at 28 hpi. Whole-genome sequencing revealed the RHeN2 strain as G9-P[23]-I5-R1-C1-M1-A8-N1-T1-E1-H1. Animal experiments demonstrated that the PoRVA RHeN2 strain exhibits strong immunogenicity and significant cross-neutralizing activity against other strains of the same genotype and G4P[23] strains. These findings lay the foundation for future research on vaccine development, G9-type PoRVA, and its pathogenic mechanisms.</p></sec></body><back><ack><title>Acknowledgments</title><p>We would like to thank the National Key Laboratory of Agricultural Microbiology Core Facility for their assistance during the experiments.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-vetsci-12-00180"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xlink:href="https://www.mdpi.com/article/10.3390/vetsci12020180/s1">https://www.mdpi.com/article/10.3390/vetsci12020180/s1</uri>, Figure S1: IFA-Mock; Figure S2: IFA-RHeN2; Figure S3: Original electron microscope image.</p><supplementary-material id="vetsci-12-00180-s001" position="float" content-type="local-data"><media xlink:href="vetsci-12-00180-s001.zip"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Z.W.: conceptualization, writing&#x02014;original draft preparation, resources, methodology, W.H.: software, methodology, visualization, G.Y.: resources, supervision, methodology, Y.T. and C.W.: validation, project administration, X.M.: visualization, formal analysis, M.S. and L.Z.: validation, formal analysis, C.Y. and H.X.: writing&#x02014;review and editing, funding acquisition, supervision. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>The study involved 28-day-old piglets from a local Hubei breed with PoRVA-neutralizing antibody titers &#x02264;1:10, housed at the Collaborative Innovation Centre for Cooperative Innovation Center for Sustainable Pig Production, Huazhong Agricultural University (HZAU). The experiments adhered to animal welfare principles and scientific ethics, with oversight from the HZAU Scientific Ethics Committee (Approval ID: HZAUSW-2023-0038, 1 January 2023).</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The data are contained within the article and <xref rid="app1-vetsci-12-00180" ref-type="app">Supplementary Materials</xref>.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare that there are no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-vetsci-12-00180"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Caddy</surname><given-names>S.</given-names></name>
<name><surname>Papa</surname><given-names>G.</given-names></name>
<name><surname>Borodavka</surname><given-names>A.</given-names></name>
<name><surname>Desselberger</surname><given-names>U.</given-names></name>
</person-group><article-title>Rotavirus research: 2014&#x02013;2020</article-title><source>Virus Res.</source><year>2021</year><volume>304</volume><fpage>198499</fpage><pub-id pub-id-type="doi">10.1016/j.virusres.2021.198499</pub-id><pub-id pub-id-type="pmid">34224769</pub-id>
</element-citation></ref><ref id="B2-vetsci-12-00180"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>H.H.</given-names></name>
<name><surname>Matthijnssens</surname><given-names>J.</given-names></name>
<name><surname>Kim</surname><given-names>H.J.</given-names></name>
<name><surname>Kwon</surname><given-names>H.J.</given-names></name>
<name><surname>Park</surname><given-names>J.G.</given-names></name>
<name><surname>Son</surname><given-names>K.Y.</given-names></name>
<name><surname>Ryu</surname><given-names>E.H.</given-names></name>
<name><surname>Kim</surname><given-names>D.S.</given-names></name>
<name><surname>Lee</surname><given-names>W.S.</given-names></name>
<name><surname>Kang</surname><given-names>M.I.</given-names></name>
<etal/>
</person-group><article-title>Full-length genomic analysis of porcine G9P[23] and G9P[7] rotavirus strains isolated from pigs with diarrhea in South Korea</article-title><source>Infect. Genet. Evol.</source><year>2012</year><volume>12</volume><fpage>1427</fpage><lpage>1435</lpage><pub-id pub-id-type="doi">10.1016/j.meegid.2012.04.028</pub-id><pub-id pub-id-type="pmid">22613801</pub-id>
</element-citation></ref><ref id="B3-vetsci-12-00180"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vlasova</surname><given-names>A.N.</given-names></name>
<name><surname>Amimo</surname><given-names>J.O.</given-names></name>
<name><surname>Saif</surname><given-names>L.J.</given-names></name>
</person-group><article-title>Porcine Rotaviruses: Epidemiology, Immune Responses and Control Strategies</article-title><source>Viruses</source><year>2017</year><volume>9</volume><elocation-id>48</elocation-id><pub-id pub-id-type="doi">10.3390/v9030048</pub-id><pub-id pub-id-type="pmid">28335454</pub-id>
</element-citation></ref><ref id="B4-vetsci-12-00180"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ferrari</surname><given-names>E.</given-names></name>
<name><surname>Salogni</surname><given-names>C.</given-names></name>
<name><surname>Martella</surname><given-names>V.</given-names></name>
<name><surname>Alborali</surname><given-names>G.L.</given-names></name>
<name><surname>Scaburri</surname><given-names>A.</given-names></name>
<name><surname>Boniotti</surname><given-names>M.B.</given-names></name>
</person-group><article-title>Assessing the Epidemiology of Rotavirus A, B, C and H in Diarrheic Pigs of Different Ages in Northern Italy</article-title><source>Pathogens</source><year>2022</year><volume>11</volume><elocation-id>467</elocation-id><pub-id pub-id-type="doi">10.3390/pathogens11040467</pub-id><pub-id pub-id-type="pmid">35456143</pub-id>
</element-citation></ref><ref id="B5-vetsci-12-00180"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hou</surname><given-names>W.</given-names></name>
<name><surname>Fan</surname><given-names>M.</given-names></name>
<name><surname>Zhu</surname><given-names>Z.</given-names></name>
<name><surname>Li</surname><given-names>X.</given-names></name>
</person-group><article-title>Establishment and Application of a Triplex Real-Time RT-PCR Assay for Differentiation of PEDV, PoRV, and PDCoV</article-title><source>Viruses</source><year>2023</year><volume>15</volume><elocation-id>1238</elocation-id><pub-id pub-id-type="doi">10.3390/v15061238</pub-id><pub-id pub-id-type="pmid">37376539</pub-id>
</element-citation></ref><ref id="B6-vetsci-12-00180"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xin</surname><given-names>Z.</given-names></name>
<name><surname>Li</surname><given-names>S.</given-names></name>
<name><surname>Lu</surname><given-names>X.</given-names></name>
<name><surname>Liu</surname><given-names>L.</given-names></name>
<name><surname>Gao</surname><given-names>Y.</given-names></name>
<name><surname>Hu</surname><given-names>F.</given-names></name>
<name><surname>Yu</surname><given-names>K.</given-names></name>
<name><surname>Ma</surname><given-names>X.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Huang</surname><given-names>B.</given-names></name>
<etal/>
</person-group><article-title>Development and Clinical Application of a Molecular Assay for Four Common Porcine Enteroviruses</article-title><source>Vet. Sci.</source><year>2024</year><volume>11</volume><elocation-id>305</elocation-id><pub-id pub-id-type="doi">10.3390/vetsci11070305</pub-id><pub-id pub-id-type="pmid">39057989</pub-id>
</element-citation></ref><ref id="B7-vetsci-12-00180"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>F.</given-names></name>
<name><surname>Luo</surname><given-names>S.</given-names></name>
<name><surname>Gu</surname><given-names>J.</given-names></name>
<name><surname>Li</surname><given-names>Z.</given-names></name>
<name><surname>Li</surname><given-names>K.</given-names></name>
<name><surname>Yuan</surname><given-names>W.</given-names></name>
<name><surname>Ye</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>H.</given-names></name>
<name><surname>Ding</surname><given-names>Z.</given-names></name>
<name><surname>Song</surname><given-names>D.</given-names></name>
<etal/>
</person-group><article-title>Prevalence and phylogenetic analysis of porcine diarrhea associated viruses in southern China from 2012 to 2018</article-title><source>BMC Vet. Res.</source><year>2019</year><volume>15</volume><elocation-id>470</elocation-id><pub-id pub-id-type="doi">10.1186/s12917-019-2212-2</pub-id><pub-id pub-id-type="pmid">31881873</pub-id>
</element-citation></ref><ref id="B8-vetsci-12-00180"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Collins</surname><given-names>P.J.</given-names></name>
<name><surname>Martella</surname><given-names>V.</given-names></name>
<name><surname>Sleator</surname><given-names>R.D.</given-names></name>
<name><surname>Fanning</surname><given-names>S.</given-names></name>
<name><surname>O&#x02019;Shea</surname><given-names>H.</given-names></name>
</person-group><article-title>Detection and characterisation of group A rotavirus in asymptomatic piglets in southern Ireland</article-title><source>Arch. Virol.</source><year>2010</year><volume>155</volume><fpage>1247</fpage><lpage>1259</lpage><pub-id pub-id-type="doi">10.1007/s00705-010-0713-1</pub-id><pub-id pub-id-type="pmid">20526785</pub-id>
</element-citation></ref><ref id="B9-vetsci-12-00180"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xue</surname><given-names>R.</given-names></name>
<name><surname>Tian</surname><given-names>Y.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Zhang</surname><given-names>M.</given-names></name>
<name><surname>Li</surname><given-names>Z.</given-names></name>
<name><surname>Chen</surname><given-names>S.</given-names></name>
<name><surname>Liu</surname><given-names>Q.</given-names></name>
</person-group><article-title>Diversity of group A rotavirus of porcine rotavirus in Shandong province China</article-title><source>Acta Virol.</source><year>2018</year><volume>62</volume><fpage>229</fpage><lpage>234</lpage><pub-id pub-id-type="doi">10.4149/av_2018_216</pub-id><pub-id pub-id-type="pmid">30160138</pub-id>
</element-citation></ref><ref id="B10-vetsci-12-00180"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wu</surname><given-names>F.T.</given-names></name>
<name><surname>Liu</surname><given-names>L.T.</given-names></name>
<name><surname>Jiang</surname><given-names>B.</given-names></name>
<name><surname>Kuo</surname><given-names>T.Y.</given-names></name>
<name><surname>Wu</surname><given-names>C.Y.</given-names></name>
<name><surname>Liao</surname><given-names>M.H.</given-names></name>
</person-group><article-title>Prevalence and diversity of rotavirus A in pigs: Evidence for a possible reservoir in human infection</article-title><source>Infect. Genet. Evol.</source><year>2022</year><volume>98</volume><fpage>105198</fpage><pub-id pub-id-type="doi">10.1016/j.meegid.2021.105198</pub-id><pub-id pub-id-type="pmid">34968762</pub-id>
</element-citation></ref><ref id="B11-vetsci-12-00180"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tao</surname><given-names>R.</given-names></name>
<name><surname>Chang</surname><given-names>X.</given-names></name>
<name><surname>Zhou</surname><given-names>J.</given-names></name>
<name><surname>Zhu</surname><given-names>X.</given-names></name>
<name><surname>Yang</surname><given-names>S.</given-names></name>
<name><surname>Li</surname><given-names>K.</given-names></name>
<name><surname>Gu</surname><given-names>L.</given-names></name>
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Li</surname><given-names>B.</given-names></name>
</person-group><article-title>Molecular epidemiological investigation of group A porcine rotavirus in East China</article-title><source>Front. Vet. Sci.</source><year>2023</year><volume>10</volume><elocation-id>1138419</elocation-id><pub-id pub-id-type="doi">10.3389/fvets.2023.1138419</pub-id><pub-id pub-id-type="pmid">37026094</pub-id>
</element-citation></ref><ref id="B12-vetsci-12-00180"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Amimo</surname><given-names>J.O.</given-names></name>
<name><surname>Vlasova</surname><given-names>A.N.</given-names></name>
<name><surname>Saif</surname><given-names>L.J.</given-names></name>
</person-group><article-title>Detection and genetic diversity of porcine group A rotaviruses in historic (2004) and recent (2011 and 2012) swine fecal samples in Ohio: Predominance of the G9P[13] genotype in nursing piglets</article-title><source>J. Clin. Microbiol.</source><year>2013</year><volume>51</volume><fpage>1142</fpage><lpage>1151</lpage><pub-id pub-id-type="doi">10.1128/JCM.03193-12</pub-id><pub-id pub-id-type="pmid">23363823</pub-id>
</element-citation></ref><ref id="B13-vetsci-12-00180"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Malakalinga</surname><given-names>J.J.</given-names></name>
<name><surname>Misinzo</surname><given-names>G.</given-names></name>
<name><surname>Msalya</surname><given-names>G.M.</given-names></name>
<name><surname>Shayo</surname><given-names>M.J.</given-names></name>
<name><surname>Kazwala</surname><given-names>R.R.</given-names></name>
</person-group><article-title>Prevalence and genomic characterization of rotavirus group A genotypes in piglets from southern highlands and eastern Tanzania</article-title><source>Heliyon</source><year>2022</year><volume>8</volume><fpage>e11750</fpage><pub-id pub-id-type="doi">10.1016/j.heliyon.2022.e11750</pub-id><pub-id pub-id-type="pmid">36468104</pub-id>
</element-citation></ref><ref id="B14-vetsci-12-00180"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ndebe</surname><given-names>J.</given-names></name>
<name><surname>Harima</surname><given-names>H.</given-names></name>
<name><surname>Chambaro</surname><given-names>H.M.</given-names></name>
<name><surname>Sasaki</surname><given-names>M.</given-names></name>
<name><surname>Yamagishi</surname><given-names>J.</given-names></name>
<name><surname>Kalonda</surname><given-names>A.</given-names></name>
<name><surname>Shawa</surname><given-names>M.</given-names></name>
<name><surname>Qiu</surname><given-names>Y.</given-names></name>
<name><surname>Kajihara</surname><given-names>M.</given-names></name>
<name><surname>Takada</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Prevalence and Genomic Characterization of Rotavirus A from Domestic Pigs in Zambia: Evidence for Possible Porcine-Human Interspecies Transmission</article-title><source>Pathogens</source><year>2023</year><volume>12</volume><elocation-id>1199</elocation-id><pub-id pub-id-type="doi">10.3390/pathogens12101199</pub-id><pub-id pub-id-type="pmid">37887715</pub-id>
</element-citation></ref><ref id="B15-vetsci-12-00180"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Zhou</surname><given-names>J.</given-names></name>
<name><surname>Zhu</surname><given-names>X.</given-names></name>
<name><surname>Bian</surname><given-names>X.</given-names></name>
<name><surname>Han</surname><given-names>N.</given-names></name>
<name><surname>Fan</surname><given-names>B.</given-names></name>
<name><surname>Gu</surname><given-names>L.</given-names></name>
<name><surname>Cheng</surname><given-names>X.</given-names></name>
<name><surname>Li</surname><given-names>S.</given-names></name>
<name><surname>Tao</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>Isolation and characterization of a G9P[23] porcine rotavirus strain AHFY2022 in China</article-title><source>Microb. Pathog.</source><year>2024</year><volume>190</volume><fpage>106612</fpage><pub-id pub-id-type="doi">10.1016/j.micpath.2024.106612</pub-id><pub-id pub-id-type="pmid">38467166</pub-id>
</element-citation></ref><ref id="B16-vetsci-12-00180"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bergman</surname><given-names>H.</given-names></name>
<name><surname>Henschke</surname><given-names>N.</given-names></name>
<name><surname>Hungerford</surname><given-names>D.</given-names></name>
<name><surname>Pitan</surname><given-names>F.</given-names></name>
<name><surname>Ndwandwe</surname><given-names>D.</given-names></name>
<name><surname>Cunliffe</surname><given-names>N.</given-names></name>
<name><surname>Soares-Weiser</surname><given-names>K.</given-names></name>
</person-group><article-title>Vaccines for preventing rotavirus diarrhoea: Vaccines in use</article-title><source>Cochrane Database Syst. Rev.</source><year>2021</year><volume>11</volume><fpage>Cd008521</fpage><pub-id pub-id-type="pmid">34788488</pub-id>
</element-citation></ref><ref id="B17-vetsci-12-00180"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Groome</surname><given-names>M.J.</given-names></name>
<name><surname>Fairlie</surname><given-names>L.</given-names></name>
<name><surname>Morrison</surname><given-names>J.</given-names></name>
<name><surname>Fix</surname><given-names>A.</given-names></name>
<name><surname>Koen</surname><given-names>A.</given-names></name>
<name><surname>Masenya</surname><given-names>M.</given-names></name>
<name><surname>Jose</surname><given-names>L.</given-names></name>
<name><surname>Madhi</surname><given-names>S.A.</given-names></name>
<name><surname>Page</surname><given-names>N.</given-names></name>
<name><surname>McNeal</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Safety and immunogenicity of a parenteral trivalent P2-VP8 subunit rotavirus vaccine: A multisite, randomised, double-blind, placebo-controlled trial</article-title><source>Lancet Infect. Dis.</source><year>2020</year><volume>20</volume><fpage>851</fpage><lpage>863</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(20)30001-3</pub-id><pub-id pub-id-type="pmid">32251641</pub-id>
</element-citation></ref><ref id="B18-vetsci-12-00180"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Burke</surname><given-names>R.M.</given-names></name>
<name><surname>Tate</surname><given-names>J.E.</given-names></name>
<name><surname>Kirkwood</surname><given-names>C.D.</given-names></name>
<name><surname>Steele</surname><given-names>A.D.</given-names></name>
<name><surname>Parashar</surname><given-names>U.D.</given-names></name>
</person-group><article-title>Current and new rotavirus vaccines</article-title><source>Curr. Opin. Infect. Dis.</source><year>2019</year><volume>32</volume><fpage>435</fpage><lpage>444</lpage><pub-id pub-id-type="doi">10.1097/QCO.0000000000000572</pub-id><pub-id pub-id-type="pmid">31305493</pub-id>
</element-citation></ref><ref id="B19-vetsci-12-00180"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Huang</surname><given-names>W.T.</given-names></name>
<name><surname>Juan</surname><given-names>Y.C.</given-names></name>
<name><surname>Liu</surname><given-names>C.H.</given-names></name>
<name><surname>Yang</surname><given-names>Y.Y.</given-names></name>
<name><surname>Chan</surname><given-names>K.A.</given-names></name>
</person-group><article-title>Intussusception and Kawasaki disease after rotavirus vaccination in Taiwanese infants</article-title><source>Vaccine</source><year>2020</year><volume>38</volume><fpage>6299</fpage><lpage>6303</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2020.07.038</pub-id><pub-id pub-id-type="pmid">32736940</pub-id>
</element-citation></ref><ref id="B20-vetsci-12-00180"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Reddy</surname><given-names>S.N.</given-names></name>
<name><surname>Nair</surname><given-names>N.P.</given-names></name>
<name><surname>Tate</surname><given-names>J.E.</given-names></name>
<name><surname>Thiyagarajan</surname><given-names>V.</given-names></name>
<name><surname>Giri</surname><given-names>S.</given-names></name>
<name><surname>Praharaj</surname><given-names>I.</given-names></name>
<name><surname>Mohan</surname><given-names>V.R.</given-names></name>
<name><surname>Babji</surname><given-names>S.</given-names></name>
<name><surname>Gupte</surname><given-names>M.D.</given-names></name>
<name><surname>Arora</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>Intussusception after Rotavirus Vaccine Introduction in India</article-title><source>N. Engl. J. Med.</source><year>2020</year><volume>383</volume><fpage>1932</fpage><lpage>1940</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2002276</pub-id><pub-id pub-id-type="pmid">33176083</pub-id>
</element-citation></ref><ref id="B21-vetsci-12-00180"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>B.</given-names></name>
<name><surname>Yi</surname><given-names>S.</given-names></name>
<name><surname>Ma</surname><given-names>Y.</given-names></name>
<name><surname>Zhang</surname><given-names>G.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Xie</surname><given-names>T.</given-names></name>
<name><surname>Li</surname><given-names>H.</given-names></name>
<name><surname>Sun</surname><given-names>M.</given-names></name>
</person-group><article-title>Immunogenicity of a scalable inactivated rotavirus vaccine in mice</article-title><source>Hum. Vaccin.</source><year>2011</year><volume>7</volume><fpage>248</fpage><lpage>257</lpage><pub-id pub-id-type="doi">10.4161/hv.7.2.14121</pub-id><pub-id pub-id-type="pmid">21307650</pub-id>
</element-citation></ref><ref id="B22-vetsci-12-00180"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhou</surname><given-names>Y.</given-names></name>
<name><surname>Wu</surname><given-names>J.</given-names></name>
<name><surname>Hu</surname><given-names>X.</given-names></name>
<name><surname>Chen</surname><given-names>R.</given-names></name>
<name><surname>Lin</surname><given-names>X.</given-names></name>
<name><surname>Yin</surname><given-names>N.</given-names></name>
<name><surname>Lu</surname><given-names>C.</given-names></name>
<name><surname>Ye</surname><given-names>J.</given-names></name>
<name><surname>Zhao</surname><given-names>Y.</given-names></name>
<name><surname>Song</surname><given-names>X.</given-names></name>
<etal/>
</person-group><article-title>Immunogenicity of inactivated rotavirus in rhesus monkey, and assessment of immunologic mechanisms</article-title><source>Hum. Vaccines Immunother.</source><year>2023</year><volume>19</volume><fpage>2189598</fpage><pub-id pub-id-type="doi">10.1080/21645515.2023.2189598</pub-id><pub-id pub-id-type="pmid">36994772</pub-id>
</element-citation></ref><ref id="B23-vetsci-12-00180"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Resch</surname><given-names>T.K.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Moon</surname><given-names>S.S.</given-names></name>
<name><surname>Joyce</surname><given-names>J.</given-names></name>
<name><surname>Li</surname><given-names>S.</given-names></name>
<name><surname>Prausnitz</surname><given-names>M.</given-names></name>
<name><surname>Jiang</surname><given-names>B.</given-names></name>
</person-group><article-title>Inactivated rotavirus vaccine by parenteral administration induces mucosal immunity in mice</article-title><source>Sci. Rep.</source><year>2018</year><volume>8</volume><elocation-id>561</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-017-18973-9</pub-id><pub-id pub-id-type="pmid">29330512</pub-id>
</element-citation></ref><ref id="B24-vetsci-12-00180"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Azevedo</surname><given-names>M.</given-names></name>
<name><surname>Saif</surname><given-names>L.J.</given-names></name>
<name><surname>Gentsch</surname><given-names>J.R.</given-names></name>
<name><surname>Glass</surname><given-names>R.I.</given-names></name>
<name><surname>Jiang</surname><given-names>B.</given-names></name>
</person-group><article-title>Inactivated rotavirus vaccine induces protective immunity in gnotobiotic piglets</article-title><source>Vaccine</source><year>2010</year><volume>28</volume><fpage>5432</fpage><lpage>5436</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2010.06.006</pub-id><pub-id pub-id-type="pmid">20558244</pub-id>
</element-citation></ref><ref id="B25-vetsci-12-00180"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yin</surname><given-names>N.</given-names></name>
<name><surname>Wu</surname><given-names>J.</given-names></name>
<name><surname>Kuang</surname><given-names>X.</given-names></name>
<name><surname>Lin</surname><given-names>X.</given-names></name>
<name><surname>Zhou</surname><given-names>Y.</given-names></name>
<name><surname>Yi</surname><given-names>S.</given-names></name>
<name><surname>Hu</surname><given-names>X.</given-names></name>
<name><surname>Chen</surname><given-names>R.</given-names></name>
<name><surname>Liu</surname><given-names>Y.</given-names></name>
<name><surname>Ye</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Vaccination of pregnant rhesus monkeys with inactivated rotavirus as a model for achieving protection from rotavirus SA11 infection in the offspring</article-title><source>Hum. Vaccines Immunother.</source><year>2021</year><volume>17</volume><fpage>5656</fpage><lpage>5665</lpage><pub-id pub-id-type="doi">10.1080/21645515.2021.2011548</pub-id><pub-id pub-id-type="pmid">35213949</pub-id>
</element-citation></ref><ref id="B26-vetsci-12-00180"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liang</surname><given-names>W.</given-names></name>
<name><surname>Zhou</surname><given-names>D.</given-names></name>
<name><surname>Geng</surname><given-names>C.</given-names></name>
<name><surname>Yang</surname><given-names>K.</given-names></name>
<name><surname>Duan</surname><given-names>Z.</given-names></name>
<name><surname>Guo</surname><given-names>R.</given-names></name>
<name><surname>Liu</surname><given-names>W.</given-names></name>
<name><surname>Yuan</surname><given-names>F.</given-names></name>
<name><surname>Liu</surname><given-names>Z.</given-names></name>
<name><surname>Gao</surname><given-names>T.</given-names></name>
<etal/>
</person-group><article-title>Isolation and evolutionary analyses of porcine epidemic diarrhea virus in Asia</article-title><source>PeerJ</source><year>2020</year><volume>8</volume><fpage>e10114</fpage><pub-id pub-id-type="doi">10.7717/peerj.10114</pub-id><pub-id pub-id-type="pmid">33150069</pub-id>
</element-citation></ref><ref id="B27-vetsci-12-00180"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Arnold</surname><given-names>M.</given-names></name>
<name><surname>Patton</surname><given-names>J.T.</given-names></name>
<name><surname>McDonald</surname><given-names>S.M.</given-names></name>
</person-group><article-title>Culturing, storage, and quantification of rotaviruses</article-title><source>Curr. Protoc. Microbiol.</source><year>2009</year><volume>15</volume><fpage>15C.3.1</fpage><lpage>15C.3.24</lpage><pub-id pub-id-type="doi">10.1002/9780471729259.mc15c03s15</pub-id></element-citation></ref><ref id="B28-vetsci-12-00180"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Thakur</surname><given-names>A.K.</given-names></name>
<name><surname>Fezio</surname><given-names>W.L.</given-names></name>
</person-group><article-title>A computer program for estimating ld50 and its confidence limits using modified behrens-reed-muench cumulant method</article-title><source>Drug Chem. Toxicol.</source><year>1981</year><volume>4</volume><fpage>297</fpage><lpage>305</lpage><pub-id pub-id-type="doi">10.3109/01480548109018136</pub-id><pub-id pub-id-type="pmid">7338208</pub-id>
</element-citation></ref><ref id="B29-vetsci-12-00180"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tamura</surname><given-names>K.</given-names></name>
<name><surname>Stecher</surname><given-names>G.</given-names></name>
<name><surname>Kumar</surname><given-names>S.</given-names></name>
</person-group><article-title>MEGA11: Molecular Evolutionary Genetics Analysis Version 11</article-title><source>Mol. Biol. Evol.</source><year>2021</year><volume>38</volume><fpage>3022</fpage><lpage>3027</lpage><pub-id pub-id-type="doi">10.1093/molbev/msab120</pub-id><pub-id pub-id-type="pmid">33892491</pub-id>
</element-citation></ref><ref id="B30-vetsci-12-00180"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pandey</surname><given-names>M.K.</given-names></name>
<name><surname>Rajukumar</surname><given-names>K.</given-names></name>
<name><surname>Senthilkumar</surname><given-names>D.</given-names></name>
<name><surname>Kombiah</surname><given-names>S.</given-names></name>
<name><surname>Singh</surname><given-names>F.</given-names></name>
<name><surname>Venkatesh</surname><given-names>G.</given-names></name>
<name><surname>Kumar</surname><given-names>M.</given-names></name>
<name><surname>Shrivas</surname><given-names>S.</given-names></name>
<name><surname>Shrivastava</surname><given-names>D.</given-names></name>
<name><surname>Singh</surname><given-names>V.P.</given-names></name>
<etal/>
</person-group><article-title>Evaluation of dynamics of immune responses and protective efficacy in piglets immunized with an inactivated porcine reproductive and respiratory syndrome vaccine candidate</article-title><source>Vaccine</source><year>2023</year><volume>41</volume><fpage>6327</fpage><lpage>6338</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2023.08.081</pub-id><pub-id pub-id-type="pmid">37689543</pub-id>
</element-citation></ref><ref id="B31-vetsci-12-00180"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Phan</surname><given-names>T.G.</given-names></name>
<name><surname>Okitsu</surname><given-names>S.</given-names></name>
<name><surname>Maneekarn</surname><given-names>N.</given-names></name>
<name><surname>Ushijima</surname><given-names>H.</given-names></name>
</person-group><article-title>Genetic heterogeneity, evolution and recombination in emerging G9 rotaviruses</article-title><source>Infect. Genet. Evol.</source><year>2007</year><volume>7</volume><fpage>656</fpage><lpage>663</lpage><pub-id pub-id-type="doi">10.1016/j.meegid.2007.05.001</pub-id><pub-id pub-id-type="pmid">17544926</pub-id>
</element-citation></ref><ref id="B32-vetsci-12-00180"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bohl</surname><given-names>E.H.</given-names></name>
<name><surname>Theil</surname><given-names>K.W.</given-names></name>
<name><surname>Saif</surname><given-names>L.J.</given-names></name>
</person-group><article-title>Isolation and serotyping of porcine rotaviruses and antigenic comparison with other rotaviruses</article-title><source>J. Clin. Microbiol.</source><year>1984</year><volume>19</volume><fpage>105</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.1128/jcm.19.2.105-111.1984</pub-id><pub-id pub-id-type="pmid">6321541</pub-id>
</element-citation></ref><ref id="B33-vetsci-12-00180"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>de Sautu</surname><given-names>M.</given-names></name>
<name><surname>Herrmann</surname><given-names>T.</given-names></name>
<name><surname>Scanavachi</surname><given-names>G.</given-names></name>
<name><surname>Jenni</surname><given-names>S.</given-names></name>
<name><surname>Harrison</surname><given-names>S.C.</given-names></name>
</person-group><article-title>The rotavirus VP5*/VP8* conformational transition permeabilizes membranes to Ca<sup>2+</sup></article-title><source>PLoS Pathog.</source><year>2024</year><volume>20</volume><elocation-id>e1011750</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1011750</pub-id><pub-id pub-id-type="pmid">38574119</pub-id>
</element-citation></ref><ref id="B34-vetsci-12-00180"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Luo</surname><given-names>S.</given-names></name>
<name><surname>Chen</surname><given-names>X.</given-names></name>
<name><surname>Yan</surname><given-names>G.</given-names></name>
<name><surname>Chen</surname><given-names>S.</given-names></name>
<name><surname>Pan</surname><given-names>J.</given-names></name>
<name><surname>Zeng</surname><given-names>M.</given-names></name>
<name><surname>Han</surname><given-names>H.</given-names></name>
<name><surname>Guo</surname><given-names>Y.</given-names></name>
<name><surname>Zhang</surname><given-names>H.</given-names></name>
<name><surname>Li</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Emergence of human-porcine reassortment G9P[19] porcine rotavirus A strain in Guangdong Province, China</article-title><source>Front. Vet. Sci.</source><year>2023</year><volume>9</volume><elocation-id>1111919</elocation-id><pub-id pub-id-type="doi">10.3389/fvets.2022.1111919</pub-id><pub-id pub-id-type="pmid">36699335</pub-id>
</element-citation></ref><ref id="B35-vetsci-12-00180"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Memon</surname><given-names>A.M.</given-names></name>
<name><surname>Chen</surname><given-names>F.</given-names></name>
<name><surname>Khan</surname><given-names>S.B.</given-names></name>
<name><surname>Guo</surname><given-names>X.</given-names></name>
<name><surname>Khan</surname><given-names>R.</given-names></name>
<name><surname>Khan</surname><given-names>F.A.</given-names></name>
<name><surname>Zhu</surname><given-names>Y.</given-names></name>
<name><surname>He</surname><given-names>Q.</given-names></name>
</person-group><article-title>Development and evaluation of polyclonal antibodies based antigen capture ELISA for detection of porcine rotavirus</article-title><source>Anim. Biotechnol.</source><year>2023</year><volume>34</volume><fpage>1807</fpage><lpage>1814</lpage><pub-id pub-id-type="doi">10.1080/10495398.2022.2052304</pub-id><pub-id pub-id-type="pmid">35593671</pub-id>
</element-citation></ref><ref id="B36-vetsci-12-00180"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shao</surname><given-names>L.</given-names></name>
<name><surname>Fischer</surname><given-names>D.D.</given-names></name>
<name><surname>Kandasamy</surname><given-names>S.</given-names></name>
<name><surname>Rauf</surname><given-names>A.</given-names></name>
<name><surname>Langel</surname><given-names>S.N.</given-names></name>
<name><surname>Wentworth</surname><given-names>D.E.</given-names></name>
<name><surname>Stucker</surname><given-names>K.M.</given-names></name>
<name><surname>Halpin</surname><given-names>R.A.</given-names></name>
<name><surname>Lam</surname><given-names>H.C.</given-names></name>
<name><surname>Marthaler</surname><given-names>D.</given-names></name>
<etal/>
</person-group><article-title>Comparative In Vitro and In Vivo Studies of Porcine Rotavirus G9P[13] and Human Rotavirus Wa G1P[8]</article-title><source>J. Virol.</source><year>2016</year><volume>90</volume><fpage>142</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.1128/JVI.02401-15</pub-id><pub-id pub-id-type="pmid">26468523</pub-id>
</element-citation></ref><ref id="B37-vetsci-12-00180"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ghonaim</surname><given-names>A.H.</given-names></name>
<name><surname>Yi</surname><given-names>G.</given-names></name>
<name><surname>Lei</surname><given-names>M.</given-names></name>
<name><surname>Xie</surname><given-names>D.</given-names></name>
<name><surname>Ma</surname><given-names>H.</given-names></name>
<name><surname>Yang</surname><given-names>Z.</given-names></name>
<name><surname>Usama</surname><given-names>U.</given-names></name>
<name><surname>Wu</surname><given-names>H.</given-names></name>
<name><surname>Jiang</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>W.</given-names></name>
<etal/>
</person-group><article-title>Isolation, characterization and whole-genome analysis of G9 group a rotaviruses in China: Evidence for possible Porcine&#x02013;Human interspecies transmission</article-title><source>Virology</source><year>2024</year><volume>597</volume><fpage>110129</fpage><pub-id pub-id-type="doi">10.1016/j.virol.2024.110129</pub-id><pub-id pub-id-type="pmid">38908046</pub-id>
</element-citation></ref><ref id="B38-vetsci-12-00180"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sadiq</surname><given-names>A.</given-names></name>
<name><surname>Khan</surname><given-names>J.</given-names></name>
<name><surname>Basit</surname><given-names>A.</given-names></name>
<name><surname>Sardar</surname><given-names>N.</given-names></name>
<name><surname>Ajmal</surname><given-names>M.N.</given-names></name>
</person-group><article-title>Rotavirus genotype dynamics in Pakistan: G9 and G12 emerging as dominant strains in vaccinated children (2019)</article-title><source>Acta Trop.</source><year>2024</year><volume>257</volume><fpage>107300</fpage><pub-id pub-id-type="doi">10.1016/j.actatropica.2024.107300</pub-id><pub-id pub-id-type="pmid">38909724</pub-id>
</element-citation></ref><ref id="B39-vetsci-12-00180"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Teodoroff</surname><given-names>T.A.</given-names></name>
<name><surname>Tsunemitsu</surname><given-names>H.</given-names></name>
<name><surname>Okamoto</surname><given-names>K.</given-names></name>
<name><surname>Katsuda</surname><given-names>K.</given-names></name>
<name><surname>Kohmoto</surname><given-names>M.</given-names></name>
<name><surname>Kawashima</surname><given-names>K.</given-names></name>
<name><surname>Nakagomi</surname><given-names>T.</given-names></name>
<name><surname>Nakagomi</surname><given-names>O.</given-names></name>
</person-group><article-title>Predominance of porcine rotavirus G9 in Japanese piglets with diarrhea: Close relationship of their VP7 genes with those of recent human G9 strains</article-title><source>J. Clin. Microbiol.</source><year>2005</year><volume>43</volume><fpage>1377</fpage><lpage>1384</lpage><pub-id pub-id-type="doi">10.1128/JCM.43.3.1377-1384.2005</pub-id><pub-id pub-id-type="pmid">15750112</pub-id>
</element-citation></ref><ref id="B40-vetsci-12-00180"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lycke</surname><given-names>E.</given-names></name>
<name><surname>Melen</surname><given-names>B.</given-names></name>
<name><surname>Wrange</surname><given-names>G.</given-names></name>
</person-group><article-title>Studies of the inactivation of poliomyelitis virus by formaldehyde</article-title><source>Arch. Gesamte Virusforsch.</source><year>1957</year><volume>7</volume><fpage>378</fpage><lpage>383</lpage><pub-id pub-id-type="doi">10.1007/BF01240745</pub-id><pub-id pub-id-type="pmid">13521953</pub-id>
</element-citation></ref><ref id="B41-vetsci-12-00180"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Umeshappa</surname><given-names>C.S.</given-names></name>
<name><surname>Singh</surname><given-names>K.P.</given-names></name>
<name><surname>Pandey</surname><given-names>A.B.</given-names></name>
<name><surname>Singh</surname><given-names>R.P.</given-names></name>
<name><surname>Nanjundappa</surname><given-names>R.H.</given-names></name>
</person-group><article-title>Cell-mediated immune response and cross-protective efficacy of binary ethylenimine-inactivated bluetongue virus serotype-1 vaccine in sheep</article-title><source>Vaccine</source><year>2010</year><volume>28</volume><fpage>2522</fpage><lpage>2531</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2010.01.039</pub-id><pub-id pub-id-type="pmid">20117268</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="vetsci-12-00180-f001"><label>Figure 1</label><caption><p>Isolation and characterization of porcine rotavirus RHeN2 from piglets exhibiting clinical diarrhea. (<bold>A</bold>) Cytopathic effects induced by RHeN2 infection in MA-104 cells and immunofluorescence detection (Monoclonal antibodies: VP6-3B8 specific to PoRVA VP6 protein; R-4C2 specific to inactivated PoRVA virions) Scale bar: 100 &#x000b5;m (<bold>B</bold>) Detection of RHeN2 in viral supernatants from F3&#x02013;F5 passages following blind transmission using RT-PCR with VP7-specific primers. (<bold>C</bold>) Transmission electron micrograph of the purified RHeN2 strain, revealing the characteristic viral morphology. Scale bar: 100 nm. <xref rid="app1-vetsci-12-00180" ref-type="app">Figures S1&#x02013;S3</xref>.</p></caption><graphic xlink:href="vetsci-12-00180-g001" position="float"/></fig><fig position="float" id="vetsci-12-00180-f002"><label>Figure 2</label><caption><p>Growth kinetics of RHeN2 in MA-104 cells (MOI = 0.2). Data represent the mean of three independent experiments, with error bars representing standard deviation. ns: not significant; * <italic toggle="yes">p</italic> &#x0003c; 0.05.</p></caption><graphic xlink:href="vetsci-12-00180-g002" position="float"/></fig><fig position="float" id="vetsci-12-00180-f003"><label>Figure 3</label><caption><p>Phylogenetic analysis of RHeN2 and other representative strains based on the nucleotide sequences of 11 genome segments, performed using MEGA11 and the neighbor-joining (NJ) method. (<bold>A</bold>&#x02013;<bold>K</bold>) Phylogenic trees based on the nucleotide of VP6, VP7, VP4, VP1, VP2, VP3, NSP1, NSP2, NSP3, NSP4 and NSP5 genes from RHeN2.</p></caption><graphic xlink:href="vetsci-12-00180-g003" position="float"/></fig><fig position="float" id="vetsci-12-00180-f004"><label>Figure 4</label><caption><p>Evaluation of the immunogenicity of the PoRVA RHeN2 strain. (<bold>A</bold>) Schematic representation of the animal experiment, including the immunization protocol and sample collection timeline. (<bold>B</bold>) Measurement of specific neutralizing antibody levels against the RHeN2 strain in the serum of piglets vaccinated with the inactivated PoRVA vaccine at various time points. ns: not significant; ** <italic toggle="yes">p</italic> &#x0003c; 0.01, *** <italic toggle="yes">p</italic> &#x0003c; 0.001.</p></caption><graphic xlink:href="vetsci-12-00180-g004" position="float"/></fig><fig position="float" id="vetsci-12-00180-f005"><label>Figure 5</label><caption><p>Neutralizing antibody titers of the PoRVA RHeN2 strain inactivated vaccine against 11 PoRVA strains. Data represent the neutralizing antibody titers against different PoRVA strains in serum from 5 piglets immunized with BEI-inactivated vaccine at 31 days post-vaccination. Error bars indicate standard deviation. ns: not significant; *** <italic toggle="yes">p</italic> &#x0003c; 0.001.</p></caption><graphic xlink:href="vetsci-12-00180-g005" position="float"/></fig><table-wrap position="float" id="vetsci-12-00180-t001"><object-id pub-id-type="pii">vetsci-12-00180-t001_Table 1</object-id><label>Table 1</label><caption><p>Primer sequences for the specific amplification of PoRVA.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Primer</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Primer Sequences (5&#x02032;&#x02192;3&#x02032;)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Product (bp)</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PoRVA-VP7-F</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CCCCGGTATTGAATATACCACAGT</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">333</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PoRVA-VP7-R</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TTTCTGTTGGCCACCCTTTAGT</td></tr></tbody></table></table-wrap><table-wrap position="float" id="vetsci-12-00180-t002"><object-id pub-id-type="pii">vetsci-12-00180-t002_Table 2</object-id><label>Table 2</label><caption><p>Primer sequences used for the amplification of the full-length genome of PoRVA.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Primer</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Primer Sequences (5&#x02032;&#x02192;3&#x02032;)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Product (bp)</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">VP1-F</td><td align="center" valign="middle" rowspan="1" colspan="1">GGCTATTAAAGCTRTACAATGGGGAAG</td><td rowspan="2" align="center" valign="middle" colspan="1">3302</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">VP1-R</td><td align="center" valign="middle" rowspan="1" colspan="1">GGTCACATCTAAGCGCTCTAATCTTS</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">VP2-F</td><td align="center" valign="middle" rowspan="1" colspan="1">GGCTATTRAAGGYTCAATGGCGTACAG</td><td rowspan="2" align="center" valign="middle" colspan="1">2690</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">VP2-R</td><td align="center" valign="middle" rowspan="1" colspan="1">GTCATATCTCCACARTGGGGTTGG</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">VP3-F</td><td align="center" valign="middle" rowspan="1" colspan="1">GGCTWTTAAAGCARTATTAGTAGTG</td><td rowspan="2" align="center" valign="middle" colspan="1">2591</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">VP3-R</td><td align="center" valign="middle" rowspan="1" colspan="1">GGTCACATCATGACTAGTGTG</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">VP4-F</td><td align="center" valign="middle" rowspan="1" colspan="1">GGCTATAAAATGGCTTCGCTAATTTACAG</td><td rowspan="2" align="center" valign="middle" colspan="1">2362</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">VP4-R</td><td align="center" valign="middle" rowspan="1" colspan="1">GGTCACATCCTTTAGAAGCTACTTATAGTCTACATTG</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">VP6-F</td><td align="center" valign="middle" rowspan="1" colspan="1">GGCTTTWAAACGAAGTCTTC</td><td rowspan="2" align="center" valign="middle" colspan="1">1356</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">VP6-R</td><td align="center" valign="middle" rowspan="1" colspan="1">GGTCACATCCTCTCACT</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">VP7-F</td><td align="center" valign="middle" rowspan="1" colspan="1">GGCTTTAAAAGAGAGAATTTC</td><td rowspan="2" align="center" valign="middle" colspan="1">1062</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">VP7-R</td><td align="center" valign="middle" rowspan="1" colspan="1">GGTCACATCATACAATTC</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">NSP1-F</td><td align="center" valign="middle" rowspan="1" colspan="1">GGCTTTTTTTATGAAAAGTCTTGT</td><td rowspan="2" align="center" valign="middle" colspan="1">1581</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">NSP1-R</td><td align="center" valign="middle" rowspan="1" colspan="1">GGTTCACATTTTTTGCTACCTAGG</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">NSP2-F</td><td align="center" valign="middle" rowspan="1" colspan="1">GGCTTTTAAAGCGTCTCAG</td><td rowspan="2" align="center" valign="middle" colspan="1">1059</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">NSP2-R</td><td align="center" valign="middle" rowspan="1" colspan="1">GGTCACATAAGCGCTTTC</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">NSP3-F</td><td align="center" valign="middle" rowspan="1" colspan="1">GGCTTTTAATGCTTTTCAGTG</td><td rowspan="2" align="center" valign="middle" colspan="1">1104</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">NSP3-R</td><td align="center" valign="middle" rowspan="1" colspan="1">GGTCACATAACGCCCCTATAG</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">NSP4-F</td><td align="center" valign="middle" rowspan="1" colspan="1">GGCTTTTAAAAGTTCTGTTCC</td><td rowspan="2" align="center" valign="middle" colspan="1">751</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">NSP4-R</td><td align="center" valign="middle" rowspan="1" colspan="1">GGWYACRYTAAGACCRTTCC</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">NSP5-F</td><td align="center" valign="middle" rowspan="1" colspan="1">GGCTTTTAAAGCGCTACAG</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">667</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NSP5-R</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GGTCACAAAACGGGAGT</td></tr></tbody></table></table-wrap><table-wrap position="float" id="vetsci-12-00180-t003"><object-id pub-id-type="pii">vetsci-12-00180-t003_Table 3</object-id><label>Table 3</label><caption><p>Design of the immunogenicity evaluation assay for the PoRVA RHeN2 strain.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Group</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Number of Piglets</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Immunization Dose</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.005mol/L BEI-inactivated</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">2 mL</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.2% formaldehyde-inactivated</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DMEM</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td></tr></tbody></table></table-wrap><table-wrap position="float" id="vetsci-12-00180-t004"><object-id pub-id-type="pii">vetsci-12-00180-t004_Table 4</object-id><label>Table 4</label><caption><p>Analysis of the individual fragments of the PoRVA RHeN2 strain.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Gene</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Segment<break/>Number</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Genotype</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Best Hit Accession</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Query<break/>Coverage%</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Identity%</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VP7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">G9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CHN/CY/LH9/2022/G9 (OQ743917.1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">99.68</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VP4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">P[23]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RVA/Pig/China/NMTL/2008/G9P[23] (JF781161.1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">95.71</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VP6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CHN/GZ/GX3/2022/G5 (OQ799862.1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">96.21</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VP1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Porcine rotavirus strain K71 (JX971580.1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">99.94</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VP2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RVA/Pig-wt/CHN/923E/2021/G9P[23] (PQ141607.1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">99</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">97.23</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VP3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">M1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RVA/Human-tc/VNM/NT0042/2007/G4P[6] (LC095893.1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">96.84</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NSP1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Human rotavirus A strain Mc345 (JN104623.1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">95.57</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NSP2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">N1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Porcine rotavirus strain JSJR2023 (PP100157.1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">97.36</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NSP3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">T1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Human rotavirus A isolate LL3354 (KC139787.1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">99</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">96.83</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NSP4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">E1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RVA/Pig-wt/CHN/GDFZ/2023/G9P[23] (PP566184.1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">99</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">97.97</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NSP5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">H1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RVA/Pig-wt/CHN/CN127/2021/G12P[7] (ON989012.1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">97.74</td></tr></tbody></table></table-wrap></floats-group></article>